. 2014 May 5;2:323–331. doi: 10.1016/j.mgene.2014.04.001

Table 4.

Patients characteristics and the CHP2 expression rates and levels in different clinical groups.

Group	No. of patients	CHP2 rates	CHP2 level (mean)	Range	p-Value
Total patient	40	13/40 (32.5%)	2.7	0–10.5
Control	10	1/10 (10%)	0.1	0–1.0	P1: 0.042^a
Sex
Male	21	7/21 (33.3%)	2.7	0–10.5	P1: 0.042^a
Female	19	6/19 (31.5%)	2.7	0–10.5	P2: 1.0
Age
Less than18	12	3/12 (25%)	1.9	0–9.5	P1: 0.042^a
At least18	28	10/28 (35.7%)	3.0	0–10.5	P2: 0.715
Type
AML	20	7/20 (35%)	3.1	0–10.5	P1: 0.042^a
ALL	20	6/20 (30%)	2.3	0–10.5	P2: 0.740
TLC
Less than 50 × 10³/μl	25	8/25 (32%)	2.4	0–10.5	P1: 0.042^a
At least 50 × 10³/μl	15	5/15 (33.3%)	3.1	0–10.5	P2: 1.0
BM blast infiltration
Less than 90%	19	7/19 (36.8%)	2.7	0–9.6	P1: 0.042^a
Total infiltration	21	6/21 (28.5%)	2.7	0–10.5	P2: 0.737
Hepatomegaly
Absent	17	4/17 (23.5%)	2.1	0–10.5	P1: 0.042^a
Present	23	9/23 (39.1%)	3.1	0–10.5	P2: 0.332
Splenomegaly
Absent	4	0/4 (0%)	0.0	0	P1: 0.042^a
Present	36	13/36 (36.1%)	3.0	0–10.5	P2: 0.284
Lymphadenopathy
Absent	13	3/13 (23%)	1.6	0–8.4	P1: 0.042^a
Present	27	10/27 (37%)	3.2	0–10.5	P2: 0.484

P1:relation of total 40 AL patients to 10 control calibrators.

P2: relation of each category to the other of the same group.

p ≤ 0.05: Significant; p > 0.05: nonsignificant.